Skip to main content
. Author manuscript; available in PMC: 2019 Aug 23.
Published in final edited form as: Sci Transl Med. 2016 Jun 1;8(341):341ra75. doi: 10.1126/scitranslmed.aad9784

Table 3.

Landmark Overall Survival GBM at First or Second Recurrence Toca 511 and Toca FC vs. Lomustine External Control

Treatment Group Toca 511&Toca FC
(N=27)
Lomustine
(N=84)
p-value
Landmark OS Rate
 OS6 96.0% 61.8% <0.001
 OS9 83.5% 38.4% <0.001
 OS12 54.8% 26.4% 0.017
 OS24 29.1% 9.1% 0.065